Bear Of The Day: BioMarin Pharmaceutical (BMRN)
We are downgrading BioMarin Pharmaceutical Inc. (BRMN) to Underperform from Neutral purely on valuation grounds as we believe that the stock is overvalued at current levels. Moreover, we are disappointed by the initial sales ramp of the company’s newest marketed product – Firdapse.
Moreover, we expect cash burn to increase since the company is investing heavily in its pipeline. Any negative news regarding the pipeline would have an adverse impact on the stock.
These concerns have caused us to widen our loss estimate for 2012 by $0.32 to $0.39 per share. Since we believe the stock is overvalued at current levels, we advise investors to avoid the name. Our target price is $35.00.
BIOMARIN PHARMA (BMRN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Best Credit Cards
Chase Freedom- Blue Cash
- Chase Sapphire
- American Express Platinum Card
- United Credit Card
- Southwest Credit Card
- Delta Credit Card
- British Airways Card - Get 100,000 Bonus Points
- Blue Cash Preferred
- Capital One Venture
- Discover Card
- Chase Ink Credit Card
- Discover More Card - 18 Month Promotional Balance Transfer
- Chase Sapphire Preferred
- Ritz-Carlton Rewards Credit Card
- Citi Diamond Preferred Card
- American Express Premier Rewards Gold Card
- Starwood Preferred Guest
- American Express Gold Card
- Citi Dividend
- Capital One Cash Rewards
- Discover Student
- Marriott Rewards Credit Card
- Marriott Rewards Premier Credit Card
- Capital One Secured Credit Card
- Hilton Rewards
- Credit Card Rewards
Broker Reviews